Will Salix contest FDA action letter for Colazal follow-on?
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Salix will request a Type A meeting including FDA's gastroenterology division director, Donna Griebel, to discuss a Dec. 22 "complete response" letter for the tablet formulation of its ulcerative colitis drug Colazal (balsalazide), the firm says Dec. 29. The action letter is the second for the new 1.1 mg tablet formulation of the 5-ASA prodrug, which was approved as a 750 mg capsule in 2000. FDA said the NDA cannot be approved in its present form, and requires clinical data from an adequate and well-controlled trial. Salix, however, declared that it "does not intend to conduct additional clinical investigation" in the indication and believes the NDA is sufficient for approval based on the firm's June 30, 2008, response to the "approvable" letter issued by FDA a month earlier, on May 16. The balzalazide tablet formulation would allow a less frequent dosing regimen of 3.3. g twice daily for mild to moderate acute ulcerative colitis
You may also be interested in...
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.